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ABSTRACT
Background: Factors found to influence outcome in

behavioral treatments for addiction include gender, drug

use severity, and age. Mental illness is often
exclusionary criteria for these studies. Therefore, little

is known about predictors of behavioral addiction
treatment response in adults with mental illness. The

current study investigates the impact of client variables
on in-treatment performance, in a contingency management
(CM)

intervention.

Methods: This research was part of a larger
randomized controlled trial of CM for stimulant abuse in

severely mentally ill adults. All clients met DSM-IV
criteria for mental illness. Demographic and service

utilization information, the Addiction severity

Index-lite, the Positive and Negative Symptom Scale, and
the Brief Symptom Scale were collected at intake.
Participants

(n = 96) received 12-weeks of CM.

In-treatment performance was based on stimulant-negative
urinalysis. Post-treatment outcomes were the average

self-reported stimulant use and average number of

stimulant-positive urinalyses during the three months of

follow-up. Linear regression was used to examine
predictors of in-treatment and post-treatment performance.

Results: Stimulant-positive urinalysis at baseline

(p = -8.19, p < .05) and higher psychiatric severity
(p = -5.25, p < .05) predicted worse in-treatment

performance. Better in-treatment performance was
associated with psychiatric service use prior to intake

(P = 2.23, p < .05).

Conclusions: Results indicate that CM treatment
performance is influenced by psychiatric severity,

service

utilization, and drug use. These data can inform CM
treatment decisions to better tailor treatment to the

needs of mentally ill clients.
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CHAPTER ONE
BACKGROUND

Co-occurring disorders

(COD), the simultaneous

presence of both a substance use disorder (SUD) and a
severe mental illness

(SMI), complicate treatment of these

conditions and diminished mental health (Bellack &
Diclemente,

1999; Dixon, 1999; Mueser, Essock, Drake,

Wolfe, & Frisman,

2001)

and substance abuse outcomes

(McLellan, Luborsky, Woody, O'Brien, & Druley,

1983).

Compared to individuals with SMI alone, patients with COD

have lower rates of treatment adherence, increased
psychotic symptoms, and a variety of other poorer outcomes
(Dixon,

1999). While treatments are being investigated to

address this problem, little is known about individual
participant factors that influence outcomes in these

treatments.

Prevalence

COD is a prolific problem in the SMI population.
Epidemiological estimates capture the scope of the problem

by examining COD patients as a subset of the general
population. One of these earliest epidemiological
estimates of COD, Reiger et al.

(1990), used data from the

1980 National Epidemiological Catchment Area Study (ECA)
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to examine the prevalence of psychiatric illness in the

general population. During the ECA researchers
administered the National Institute of Mental Health

Diagnostic Interview to over 20,000 people in five U.S.
states using a combined community household, hospital
inpatient, and long-term care facility sample. Analysis of
this data found rates of lifetime alcohol dependence and

drug dependence in the SMI population at 28.9%.

In the

non-SMI population the rate of any alcohol or drug

disorder found was 13.2%. Compared to the non-SMI
population this represented a 2.7 fold increase in the

likelihood of having a drug or alcohol use disorder if an
SMI is present.

Individual Impact of Co-Occurring Disorders

People with both SMI and SUD suffer greater negative
consequences of drug use than do populations with only one

of these issues. This can be seen in greater levels of

psychiatric symptoms, higher levels of interpersonal

violence, and increased homelessness. Drug use has been

found to exacerbate psychotic symptoms and relapses in

schizophrenic patients, when compared to schizophrenic
persons without drug use (Negrete, Werner, Douglas,
Smith,

&

1986) . Interestingly, this effect is amplified by
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medication non-compliance. Owen, Fischer, Booth, and
Cuffel (1996)

studied medication compliance in two groups

of mentally ill adults, one with COD and one without.

After 6 months they found treatment non-compliance in the

COD group to be 8 times higher than in the non-COD,

SMI

only, group. More recently, Lipsky, Krupski, Roy-Byrne,
Mancsuso, and Hubler (2009)

found a 30% decrease lower

rate of treatment completion, and a higher likelihood of
multiple costly reentries into treatment programs for
people with COD. This research demonstrates that people

with COD can be more difficult to treat, demonstrate lower

adherence to treatment and display more guarded outcomes
than patients with SMI.

Sociological Impact
Members of the COD population do not bear the cost of

their difficulties alone. From a sociological standpoint
they have a disproportionately large footprint on social

and legal services they utilize. McNeil, Binder, and
Robinson (2005) analyzed jail bookings in the San

Francisco County Jail system during the first 6 months of
2000. Examination of these records revealed that the
charges filed against inmates with a diagnosed COD were

more likely to have involved violent crimes,
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such as

assault and robbery,

than those without CODs.

Additionally, the presence of a COD predicted a
significantly longer prison stay by 16.5 days. Bartels et

al.

(1993)

compared the jail and hospital utilization

behaviors of people with only SMI to those with COD. He
found that participants with COD were significantly more

likely to have higher numbers of incarcerations,

inpatient

psychiatric hospitalizations, and inpatient substance

abuse hospitalizations. These COD participants had

institutional stays averaging 40 times longer, and were
twice as likely to utilize costly acute care services such

as emergency rooms and crisis stabilization as their

non-drug using counterparts.

Treatments for Co-Occurring Disorders

Despite the large negative impact COD has on the
patient and society at large, the problem is treatable.
When treatment is successful, appreciable cost-savings can
be seen. Jerrell, Hu, and Rudgely (1994)

followed COD

patients through three different types of substance abuse

treatment: 12-step, Case management and a behavioral
skills training. All three interventions yielded a

reduction in acute care utilization such as emergency room
visits and non-acute care utilization. With treatment,
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cost of care for these patients decreased by as much as
43%. Other Studies have shown promising outcomes for

pharmaceutical treatments, such as methadone,

for patients

with mood or psychotic disorders who abuse opiates.

Unfortunately, there is no pharmaceutical treatment for
stimulant abuse analogous to opioid replacement, leaving

only psycho-social treatment options.

Contingency Management
Contingency Management (CM), a reinforcement based

psycho-social treatment, has a history of success in
treating people with SMI (Bellack, Bennett, Gearon, Brown,

& Yang, 2006), and stimulant addiction (Higgins et al.,

1994; Higgins et al., 1991; Peirce et al., 2006; Roll et
al.,

2006; Shoptaw et al., 2006). Grounded in operant

conditioning, CM aims to provide reinforcers for desired

behavior (substance abstinence), on a schedule that is

incompatible with undesired behaviors

(drug use). For CM

to be effective, the value of the reinforcer must be high

enough to compete with the intrinsic reinforcement of the
drug use and come soon enough after the objective measure

of drug abstinence to be temporally related. In practice,
onsite urinalyses have been a quick and convenient tool to

provide verification of drug abstinence. CM reinforcers
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have taken many different shapes including vouchers for

food (Peirce et al., 2009; Peirce et al., 2006),
remuneration of client funds

(Ries, Short, Dyck,

&

Srebnik, 2004), low cost incentives (Peirce et al., 2006),

and even employment
Bigelow,

(Silverman, Svikis, Robles, Stitzer,

2001; Silverman et al., 2002). In non-SMI

populations SUD treatment decisions have been informed by
research examining variables that predict treatment
outcome. These findings allow clinicians to target

treatment opportunities at the clients most likely to
succeed, or to tailor CM interventions when clients

possess fewer variables predicting success, thus

preventing costly treatment failures and treatment

re-admissions (Amodeo, Chassler, Oettinger, Labiosa,
Lundgren,

&

2008) . Unfortunately severe mental illness acts

as exclusionary criteria for most substance use treatment

outcome research (Dubois,

2008)

limiting generalizability

to this population. Towards this end, this study examines
potential client predictors of treatment outcome during a
12 week CM intervention.

6
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CHAPTER TWO

REVIEW OF THE LITERATURE

In substance abuse treatment research, baseline
client characteristics have long been found to impact the
outcome of treatment. Of the client level characteristics

investigated,

the following have been repeatedly-

associated with substance abuse treatment outcomes:

results of urinalysis at baseline time point (Preston et

al., 1998), severity of substance dependence (Babor,
Dolinsky, Rounsaville, & Jaffe,
support

1988) availability of

(Havassy, Hall, & Wasserman, 1991), psychiatric

symptom severity (McLellan et al., 1983; Rounsaville,

Dolinsky, Babor, & Meyer, 1987) and male gender,

(Compton,

Cottier, Jacobs, Ben-Abdallah, & Spitznagel, 2003) .

Unfortunately, SMI diagnosis is often used as exclusionary
criteria for studies investigating predictors of treatment
outcome. Below, studies of client level variables that

impact substance use treatment outcome in non-SMI, and SMI
populations are reviewed.

Predictors of Treatment Outcome in Non-Mentally
Ill Substance Users
A novel Study by McLellan et al.

(1994)

investigated

baseline variables as predictors of treatment outcome
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across differing substance use disorder treatments.
Participants consisted of 649 adults enrolled in substance

abuse treatment for alcohol, opiates, or cocaine. While
the type of treatment received by these patients varied

widely, all patients did receive standardized interview
measures at baseline and throughout follow-up. The 22

individual treatment locations included methadone
maintenance programs, along with inpatient and outpatient

SUD treatment for alcohol and cocaine. The Addiction

Severity Index (ASI), a multi-dimensional measure of drug
use severity, was collected from each participant at

intake, and again at 6-month follow-up by a trained
interviewer. Additionally, the Treatment Services Review

(TSR), a brief survey of professional services utilized,

was taken weekly while patients were in treatment. Changes

in the composite scores derived from the ASI were the
outcome measure of interest. The ASI composite scores

measure multiple separate dimensions of functionality that

may be impacted by substance addiction; drug and alcohol

use severity, psychiatric and medical issues, legal
problems, family and social issues, employment problems.

Additionally, ASI answers can be used to create a global
level of functioning.
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To examine these data, researchers used a

hierarchical stepwise multiple regression analysis for
each of the outcome measures. Results from these analyses

suggest that demographic factors

(e.g., race, age, gender,

education, etc.) were not significantly related to
treatment outcome, accounting for less than 5% of the
variance together. Baseline severity of all ASI composite
scores accounted for 12% of the variance in the treatment
outcome at 6-months. ASI Drug and alcohol use severity

scores at baseline both accounted for 4% variance of
treatment outcome at 6-months. The other 4% of variance

was split between ASI medical severity and ASI psychiatric

severity score. This pattern of prediction was similar
regardless of which substance a patient was being treated

for but differed in magnitude by substance used. The ASI

composite scores predicted 45% of variance in outcome for
those in opiate treatment at 6 months compared with the
more modest amounts of variance in cocaine treatment

(8%)

or alcohol treatment (15%). Number of treatment services

utilized, as measured by the TSR, was associated with
better treatment outcomes despite differences in treatment

site and treatment modality.
These findings suggest that client level predictive

variables may be consistent across populations of drug
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.users, despite differences in drugs used. Additionally,
the similarities in predictors,

found with multiple

different sites and modalities,

suggest baseline client

variables that influence outcome may do so regardless of
where and how treatment is received.
More recently Hillhouse et al.

(2007)

investigated

predictors of in-treatment performance and post-treatment
outcomes in a sample of 420 adult methamphetamine

dependent outpatients. This research was done as part of a
larger study investigating psychosocial treatment for
methamphetamine which included intensive outpatient,

cognitive behavioral therapy, support groups,

family

education on substance use, and individual counseling.

Additionally, participation in 12-step meetings was also
encouraged. Participants who had a serious mental illness
as measured by the DSM-IV, and participants who had a
serious medical condition were excluded from this study.

Baseline data were collected one week before treatment,

during treatment, at discharge, and six and 12 months
post-treatment. Urinalysis testing for methamphetamine use
were collected Baseline, weekly during treatment, and at
both six and 12-month follow up appointments. Data

collected at baseline included demographic

characteristics; gender, ethnicity, and educational level,
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the ASI and. the Craving Frequency, Intensity and Duration
Estimate

(CDIFE), which is a self-report scale of

methamphetamine craving intensity and frequency.
In-treatment performance measures included engagement,

retention, and abstinence. Engagement was measured as the
completion of the first two weeks and the first 30 days of
treatment. Retention was measured as the number of weeks
of treatment attended (16 weeks possible) . Abstinence
while in treatment was quantified in two different ways,

mean number of methamphetamine negative urinalysis
submitted during treatment, and by submission of three
consecutive methamphetamine-negative urinalysis.

Of this sample,

67.1% meet criteria for early

engagement, completing the initial two weeks of treatment.
Examination of baseline predictors showed that being

female, having had used methamphetamine greater than

15 days in the month prior to baseline,

smoking

methamphetamine, and having a history of methamphetamine

use less than two years were associated with poorer
initial treatment engagement.

At the later engagement time point,

30-days,

56% of

participants remained in treatment. Again, female gender,
higher rate of use during the month, before treatment
predicted dropout prior to this time point. Additionally,
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depression at baseline was also associated with dropout

before 30-days of treatment.
Baseline characteristics influenced clients' overall

retention, as expressed by the number of weeks of
treatment completed. Higher frequency of methamphetamine

use in the month prior to baseline, and methamphetamine
use during treatment, as measured by percent of clean
urinalysis submitted during treatment were associated with

a reduction in the number of weeks of treatment completed.
Predictors of abstinence, dichotomously measured by
whether or not a participant was able to provide three or
more consecutive urinalyses, were investigated using

logistic regression. Female gender, 15 days or greater
methamphetamine use prior to baseline, and route of

administration (smoking or injection) were associated with

non-abstinence during treatment participation.
Post-treatment outcomes consisted of urinalysis
collected at the 2 post-treatment time points

(three and

six months) along with self-report methamphetamine use,

and single urinalysis at during the interview.
Methamphetamine use of 15 days or greater in the month

prior to baseline was the most consistent predictor of
poorer post-treatment outcomes. Injection drug use,

attendance to previous drug treatment,
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life-time history

or 2 or more years of methamphetamine use, depression and

Asian ethnicity were also associated with higher
methamphetamine use during the three and six month
post-treatment time points. Abstinence, and completion of

the entire 16-weeks of treatment, predicted
methamphetamine abstinence during post-treatment time

points.
The severity of use in the month prior to baseline is
a consistent predictor across all time-points measured.

This suggests it is an important factor in predicting
treatment outcome and should be pursued in any
investigation of baseline predictors. Interestingly, the
gender finding suggesting females are less likely to

initiate and complete treatment is evidence that
demographics can play a role in treatment adherence.

Unfortunately, it was not reported rather females who
dropped out of treatment early were included in analysis

of follow-up outcome. If females who dropped out were not

included, it would undermine the influence that the gender
variable could have as a predictor in the ultimate
treatment outcome.

Garcia-Fernandez et al.

(2011) also investigated

client level predictors of substance use disorders, but
focused on Cocaine addiction treatment with a CM based
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psycho-social intervention. This research utilized a

Community Reinforcement Approach (CRA), a standardized
psycho-social treatment for addiction, plus vouchers

(Brundy & Higgins, 1994). The "vouchers" component of this
treatment was an adjunct CM incentive based reinforcement
program. The primary outcome of interest was cocaine

abstinence at six months of treatment as measured by

agreement in urine toxicology (UA) , self-report measures,
and family report.
Participants in this study were predominately male

(82%) with a mean age of 31.4
criteria were age,

(SD = 6.0). Inclusion

20 years or older, and meeting the

criteria for cocaine dependence as defined by the DSM-IV.
Participants with active opioid dependence, and serious

psychopathology disorders, such as psychotic or bi-polar
disorder, were excluded. The sample was a combination of

two smaller samples from randomized clinical trials of CRA

plus voucher outpatient programs. This resulted in a final
N of 50.
At intake, Participants were assessed with the

Michigan Alcoholism Screening test (MAST; Seizer,

1971),

the Beck Depression Inventory (BDI; Beck, Ward, Mendelson,

Mock, & Erbaugh, 1961), the DSM-IV-TR criteria for cocaine

dependence, the European Addiction Severity Index (EASI;

14

Kokkevi & Hartgers, 1995), and the Symptom

checklist-90-Revised (SCLR-90-R; Derogatis,

1983). All

participants then received 6 months of CRA plus voucher

treatment, submitting 3 UAs a week for the first three
months,

then 2 Uas a week the final 3 months.

Analyses were done to confirm there were no
significant demographic differences between the

populations of the two CRA plus voucher RCT studies. Then

a Logistic regression analysis was performed using

baseline client variables and UA results at week four to
predict cocaine abstinence at six months of treatment. A

regression model containing EASI alcohol composite scores

and UA results from week 4 was statistically significant
in predicting cocaine free UA at the 6 month time point.

This model accounted for 32.2 % of the variance,

and

correctly identified 76% of cases.

Interestingly, unlike the other previously mentioned
studies, psychiatric severity (as measured by ASI)

did not

influence UA results at 6 months. This may have been due

to the exclusion of participants who exhibit severe mental
illness from participating in this study. Another unique

facet of this study was their examination of treatment
success at 4 weeks as a predictor. Previously, results of

the first UA have shown predictive ability for treatment
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outcome (Preston et al.,

1998), the 4 week UA results were

not only useful in the prediction model but were also the
strongest predictor of the 6 month UA results with an odds
ratio of 14.9. This means participants were nearly 15

times more likely to have a clean UA at 6 month,

if they

had a stimulant clean UA at the 4-week time point. While
generalization to an SMI population may be limited due to

the exclusionary criteria of this study, their findings

demonstrate that client level variables, including
in-treatment performance, can predict treatment outcome in

a CM plus psychosocial treatment.

As in the previous study, adults with SMI are often

excluded from SUD research (Dubois, 2 0 08) . This population
poses unique challenges in treatment and tracking.

Reviewed below are studies investigating the impact of
individual client-level characteristics on treatment
outcomes involving SMI individuals that examine both
clinical and client level predictors of treatment
outcomes.

Predictors of Substance use Treatment in Severe
Mental Illness Substance-Abusing Populations

Brown, Bennett, Li, and Bellack (2011)

investigated

predictors of initiation and engagement in psycho-social
substance abuse treatment programs for the severely
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mentally ill. For the purposes of the study the

researchers defined initiation as completion of the

initial baseline assessments (2 appointments totaling 2.5
hours long)

and engagement as attendance to the first 3 or

more appointments.

In the parent study, participants were

randomized to one of two different psycho-social
interventions: Behavioral Treatment of Substance Abuse in

Schizophrenia (BTSAS; Bellack et al., 2006) and Supportive

Treatment in Addiction Recovery (STAR). BTSAS was a
combination of motivational interviewing techniques,

CM,

goal setting, coping skill training, education, and
relapse prevention. STAR was a twice a week,

six month

long mock support group for addiction problems where
participants chose the topic for group discussion. It
served to yoke the amount of time the two conditions spent

in a supportive drug treatment group environment.
Participants in this study were predominately male
(64%)

and non-Caucasian (77%), with a mean age of 42.1

(SD = 7.9). All participants consented and met diagnostic
criteria for SMI: 38% schizophrenia or schizo-affective,

38% major depressive recurrent, 17% bipolar,

psychiatric disorder. Additionally,

and 7% other

all clients met

-criteria for a substance use disorder, either abuse or

dependence as defined by DSM-IV.
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Variables chosen for examination were done so based

on previous research regarding treatment initiation and
engagement in non-SMI populations along with clinical

experience with SMI populations. These variables included
demographic variables: age, race, gender,

education, and

veteran status; Clinical variables: Diagnosis, number of
days in an inpatient psychiatric hospital, and Positive

and Negative Symptom Scale (PANSS; Kay, Fiszbein,

& Opler,

1987) rating (a psychiatric symptom rating assigned by the

interviewer); Substance abuse variables: Abuse or
dependence as measured by the DSM-IV, as well as the
Addiction Severity Index (ASI; McLellan et al., 1992)
rating of lifetime and recent drug use; Legal variables

such as recent arrest, and type of crime: as measured by
the ASI; Family and social problems variables,

such as

recent arguments: as measured by the ASI and the Brief
Quality of Live Interview (BQOL; Lehman,

1995). Using a

Chi Square test researchers first performed a univariate
comparison of the aforementioned variables of those who
finished initiation to those who did not. Any variable

showing a difference of p < .10 or lower were then

examined using a multivariate logistic regression model to
examine predictors. Non-significant predictors were

removed until all predictors had a p-value of .10 or
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lower. Finally, any predictors with p-values < .05 were

considered statistically significant. Similar methodology
was used to examine variables predicting treatment

engagement, but only participants who finished baseline

were included in this analysis. All randomized
participants from both treatment groups were used for this
analysis.

Ultimately the Brown, Bennett, Li, and Bellack
regression model showed male clients with schizophrenia
spectrum disorders were less likely to initiate treatment

(complete the baseline assessment). Treatment engagement

was predicted by a clients' rating of positive feeling
towards their families. Lack of treatment engagement was

predicted by recent arrests and a current diagnosis of
drug dependence. Only data for the BTSAS were examined for

this data (Robins, Helzler, Cottier,

& Golding,

1989).

It is not hard to imagine that successful entry into
a drug treatment program is the first positive outcome
achieved in a treatment. In this psychosocial intervention

with a CM component, we can see by this research that
individual level characteristics, including clinical

characteristics such as psychopathology as measured by the
PANSS and addiction severity as measured by the ASI, can

influence success in treatment.
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Compton,

Cottier, Jacobs, Ben-abdallah,

and

Spitznagel (2003) also examined the impact of psychiatric

disorders have on 1-year post-treatment outcomes in drug
abuse. Participants were drawn from a sample of 512

patients in a larger study on drug abuse and HIV risk
behavior. All participants were receiving drug treatment

in a variety of outpatient,

inpatient, and specialized

treatment settings consisting of two outpatient methadone

clinics, three outpatient substance abuse programs, two
inpatient substance abuse programs, and a residential

recovery shelter.
Inclusionary criteria consisted of dependence on at

least one illicit substance for the 425 participants
chosen for this research. Clinical diagnosis,

including

drug dependence, was assessed using the National Institute

of Mental Health Diagnostic Interview Schedule, version
III-R (DIS III-R; Robins et al., 1989)

and the NIDA Risk

Behavior Assessment (Needle et al., 1995). Variables

chosen for examination were demographic variables: race,

education, marital status, employment status, and family
status; drug use variables:
cocaine, heroin,

lifetime dependencies on

cannabis, other opiates, amphetamine,

sedative, and phencyclidine; and clinical variables:
generalized anxiety, major depression phobia, panic
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disorder,

dysthymia, mania, antisocial personality

disorder,

schizophrenia, obsessive compulsive personality

disorder, anorexia, and bulimia. Two additional variables

were created called "any psychiatric disorder" which

combined the presence of any of the psychiatric disorders,
and "number of disorder" which identified the number of
co-morbid disorders the participant possessed. The 1-year
post treatment outcomes examined were: number of illicit
drugs used 1-year post treatment, number of DIS DSM-III-R

criteria for dependence on illicit drugs met, number of
illicit drugs participant met full dependence criteria for
as per the DIS DSM-III.

Co-morbid Psychiatric diagnoses were tested as
predictors of outcome at 1-year post treatment.

Demographic variables, and co-morbid psychiatric disorder
was tested separately using a Wilcoxon test to examine

differences in the outcome variables, number of illicit
drugs used, amount of criteria for dependence met, and

number of illicit drugs participants met full dependence
criteria for. Demographic variables and psychiatric

variables acted as the predictor variables in these
models, and the Bonferroni correction was used to protect

against Type II error.
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Results revealed that major depressive disorder had
significant impact on 1-year post-treatment outcomes,
predicting a higher number of drugs used, a higher number

of dependence criteria met, and a higher number of drugs
meeting full criteria for dependence. Anti-social
personality disorder trended toward predicting a great

number of substances used, but did not reach significance

due to the Bonferronni correction. Additionally,
generalized anxiety disorder and dysthymia trended towards

significance for predicting negative outcomes, while
phobic disorders trended towards predicting positive

outcomes. When these regression models were split by
gender,

the researchers found antisocial personality

disorder, and major depression had a significant negative

impact on drug use outcomes 1-year post treatment in
males.

The Compton et al. sample was comprised of adults

attending a variety of different drug treatment programs.
The most common psychiatric disorder of this sample was
alcohol dependence. While alcohol dependence is a common

axis one disorder, it is qualitatively different than
other types of major mental illness. Additionally, Bipolar

disorder and schizophrenia were both excluded from
analysis due to them being present in less than 10% of the
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sample. This lessens the generalizability of these finding

for people who have more severe mental illness. One-year

post treatment outcomes were analyzed, but there was no
standardized treatment modality delivered across treatment

sites. While, this study provides evidence that

psychiatric status influences SUD post-treatment outcomes,
it can be difficult to interpret how these findings can be

applied clinically.
Similar evidence of the influence of psychiatric
symptomology on psychosocial treatment outcome can be seen

in Peirce et al.

(2009). In this study researchers

examined data from 800 stimulant users participating in
and RCT for CM while enrolled in an alternate substance
abuse treatment program. These participants were either
enrolled in methadone maintenance programs or outpatient
psychosocial drug treatment program. Their goal was to
examine if stimulant abusers would differ by treatment

modality; either methadone maintenance with CM or

psychosocial outpatient treatment with CM. At intake,
participants completed a truncated version of the ASI, and
the full Brief Symptom Index (BSI; Derogatis, 1992).

Urinalysis and a breath sample were also collected at
baseline. During the intervention, participants submitted

two urinalyses per week for 12 weeks of CM treatment. The
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researcher chose 23 separate variables to predict
treatment outcome in both groups. Social variables such as

marital status,

living situation and current employment

were taken from the ASI. Drug use severity was also taken
from the ASI. Demographic variables, age, gender, race

were gathered at intake. Psychiatric distress variables
were taken from the global BSI composite score. The
dependent variable, chosen by researchers, was total

number of stimulant free urine samples during treatment.

Data were analyzed using regression modeling. All
independent variables entered simultaneously. The
regression models were then compared by treatment

location.

Results showed that, once again, a stimulant positive
urine sample at intake was a powerful predictor of post

treatment outcome at both locations.

Interestingly, other

predictors differed by modality. For instance, psychiatric
distress was associated with poorer performance in
treatment for participants receiving psychosocial
substance abuse and CM treatment, but not for patients in

methadone plus CM treatment programs. Methadone
maintenance patients, but not psychosocial patients, had

poorer treatment outcomes when they were living with

someone who was using drugs, or they continued to
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associate with a drug-related lifestyle. History of

employment was a positive predictor of treatment success
for the group receiving psychosocial treatment; in the

methadone group, having current employment was associated
with more stimulant positive urines during treatment.
These results paint a compelling but confusing

picture of research investigating predictors of substance
abuse treatment outcomes. They also underscore the fact

that client level variables influence treatment outcome in
CM and other treatments but highlight the limited
generalizability by the wide exclusion of SMI populations.

Variables are observable across treatment,

location, and

treatment modalities. Common themes in predictor variables

were; demographic variables, substance use variables,
psychiatric variables, and service utilization variables.

Hypotheses
Prior research has shown that client level variables

can be predictive of stimulant SUD treatment outcomes, CM

SUD treatments outcomes, and SUD treatment outcomes for
the mentally ill. Reliably, these client level variables
that predict treatment outcome have fallen into four

separate dimensions; Demographic variables, drug use

variables, psychiatric variables, and service utilization
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variables. Based on previous research,

it is proposed

that:
1) Demographic factors; gender, age, race will be

used to predict in-treatment performance as
measured by consecutive stimulant-clean urinalyses
submitted during treatment, and post-treatment

outcome as measured by self-report number of days

of stimulant use in the previous month and
stimulant-positive urinalyses during follow-up.
Female gender is expected to predict poorer

treatment outcomes. Higher age will be associated
with better treatment outcomes.

2) Drug use as measured by baseline urinalysis

(stimulant positive or stimulant negative), and
ASI drug use severity composite score will predict

in-treatment performance as measured by
consecutive stimulant-clean urinalyses submitted
during treatment, and post-treatment outcome as
measured by self-report number of days of

stimulant use in the previous month,

and

stimulant-positive urinalyses collected during

follow-up. Additionally, for the post-treatment
outcome analysis only,

in treatment performance

will be used as a predictor

26

3)

Psychiatric severity, as measured by BSI global
score, and PANSS composite score, and presence of
schizophrenia-spectrum disorder vs. mood disorder

will predict in-treatment performance as measured

by consecutive stimulant-clean urinalyses

submitted during treatment, and post-treatment
outcome as measured by self-report number of days
of stimulant in the previous month, and

stimulant-positive urinalyses collected during

follow-up. Specifically higher ratings of
psychiatric severity will predict poorer

in-treatment and post-treatment outcomes.
Schizophrenia-spectrum disorders will be

associated with poorer outcomes in-treatment and
during post-treatment.

4) Recent service utilization, as measured by the

Self-Report Service Utilization (SRSU)
questionnaire assessing self-report outpatient
psychiatric service contacts or substance abuse

service contacts in the prior week, will

in-treatment performance as measured by
consecutive stimulant-clean urinalyses submitted
during treatment, and post-treatment outcome as

measured by self-report number of days of

27

stimulant in the previous month, and
stimulant-positive urinalyses collected during

follow-up. Specifically recent involvement in
services is expected to predict better
in-treatment and post-treatment outcomes.
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CHAPTER THREE

METHODS

Participants

Participants were recruited through an urban
community mental health care agency in Seattle,
Washington. Participants in the study were recruited as

part of a larger randomized clinical trial of CM for

stimulant abuse in a severely mentally ill population.

Inclusion criteria included meeting current Mini

International Neuropsychiatric Interview (MINI)

criteria

for severe mental illness: recurrent major depressive
disorder, bipolar I, bipolar II, or schizophrenia. At time
of enrollment the patients must also have been between the

ages of 18 to 65. Finally, patients had to have met
criteria for Stimulant dependence as defined by the MINI,

and have had endorsed stimulant use in the last 30 days.
Exclusion criteria included suffering from another organic

brain disorder; report of a trauma history that may
complicate diagnosis; and any medical or psychiatric

condition that would have compromised safe study

participation, such as a severe history of violence
towards clinic staff.
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In total, 205 participants provided informed consent
as approved by the University of Washington's Human

Subjects Division. Of the 201 participants who finished
the baseline interview 197 met all criteria for
enrollment. The initial five participants were assigned to

the CM treatment condition, this was done to determine the
level of reinforcement the yoked, non-treatment group

received. After the initial level of reinforcement was
determined participants were randomized into either the CM
treatment condition or the control

(non-CM)

condition. Of

the resulting 192 participants eligible for randomization,

only 176 attended their randomization visit. Only
participants who received active CM treatment were
included in this analysis

(n = 96, mean ± SD age, 45 ± 8.9

years; 32% female; 49% European-American, 36%

African-American and 14% Other Ethnicity)

Design

The CM RCT was a 3 month quasi-yoked trial of CM with

a three month follow-up period. The CM intervention

targeted stimulant use behavior. Participants received
treatment as usual

(TAU) plus CM for stimulant use or TAU

without CM. Participants were randomized using a blocked

randomization procedure balancing both groups on severity
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of substance use in the last 30 days, SMI diagnosis
(schizophrenia-spectrum disorder vs. mood disorder), and

psychiatric hospitalization in the last year, and gender.
Only data from participants who received active CM
treatment plus TAU were analyzed for the current study.

Procedure
After consent was provided, participants completed

all study baseline measures including the MINI
International neuro-psychiatric interview (MINI)

interview,

the Brief Symptom interview (BSI), The Positive

and Negative Syndrome Scale (PANSS), the Addiction

Severity Index (ASI), and others not used for this

research. Participants were informed of their group
randomization at their first visit, Treatment visits took
place on Mondays, Wednesdays, and Fridays for twelve

weeks. If a visit was preempted by a holiday it would be

moved to the next available day, usually a Tuesday or

Thursday. Participants received prize draws based on their
treatment condition. At weeks 4,

8, and 12 of treatment,

and 16, 20, and 24 of follow-up, participants completed
semi-structured interviews consisting of the same measures
mentioned above, but without the MINI. Participants were

remunerated with $30 in gift-cards to local grocery stores
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after completing the initial baseline appointment, and 20$
in gift-cards for follow-up visits.
Outpatient mental health and outpatient substance use

treatment, inpatient mental health and substance abuse
treatment, emergency room visits, and incarceration were
assessed using data provided by King County. These data
were provided for 3 months prior to study participation,

during the 3 months of study treatment, and during the
3-month follow-up period.
Treatment as Usual

The community mental health clinics, where patients

were recruited, provided Treatment As Usual (TAU) to all
study participants. TAU included weekly meetings with a

case manager and additional mental health, chemical

dependency, housing and vocational support as decided on
by the client. Clients also received psychiatric visits as

needed for medication management.

Contingent Management Treatment Condition
During the active treatment period, participants in

the CM treatment group provided urine samples 3 times per
week for the 12 weeks of treatment. These urine samples
assessed for amphetamine, methamphetamine, cocaine,
marijuana, and opiate use. Participants who tested

negative for illicit stimulants were allowed to
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participate in the variable magnitude reinforcement

procedure (VMRP; Petry, Alessi, Marx, Austin,

& Tardif,

2005). The VMRP involves making "prize draws" from a bin
of tokens representing different levels of reinforcement.
Of the 501 tokens in the bin,

50% (250)

of the tokens say

"good job" and did not deliver tangible reinforcement,
41.8% (210) of the tokens say "small" and allow

participants to choose from the available small prizes,

8% (40) of the chips read "large" and allowed participants
t‘o choose a large prize, and .02% (1) of the chips read

"JUMBO!" and allowed the participant to choose from one of
the JUMBO prizes. Small prizes consisted of daily care
needs such as toothpaste, socks, snacks, and sundries

valued at $1. Large prizes consisted of portable music
players,

small kitchen appliances, and gift cards valued

at $20. Jumbo prizes were portable movie players, large

appliances or $80 in gift cards valued’ at $80. At their
initial randomization visits, participants who provided a

urinalysis clean for stimulants received one chance to

engage in the VMRP. Participants' VMRP draws increased by
one for every week of stimulant clean urinalyses provided,

up to 12 weeks. A participant who never submitted
stimulant positive urine would earn 14 draws per visit. If
participants provided a stimulant positive urinalysis or
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missed an appointment their chances to engage in the VMRP

were reset to 1 for every clean urinalysis. Participants
were able to earn back their lost draws if one full week

of clean urinalyses were provided. This reinforcement

schedule is based on previous research (REFS). At each
visit participants received one additional VMRP draw for

being clean for alcohol, opiates, and marijuana. This one

additional draw was consistent across time and did not
increase like the stimulant draws.

Measures
Urinalysis

Recent drug use was assessed using onsite
immunoassays assessing urine samples for amphetamine,

methamphetamine, cocaine, metabolites

(Integrated E-Z

Split Key® Cup, Iimovacon, Inc, San Diego,

CA). Detection

of stimulant drugs is generally assumed to be feasible for

up to 3 days after use (Beckett, Tucker,

& Moffat, 1967).

Participants provided urine samples three times per week

(Monday/Wednesday/Friday) . A maximum total of 36 urine
samples were possible during in-treatment. During

follow-up, participants provided urine samples once

per-month at their three post-treatment interviews.
Urinalysis results served as the dependent variable for
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iii-treatment performance. This was operationalized as the
highest number of consecutive stimulant-negative urine
samples that was not interrupted by a absence or refusal

to submit a sample during the treatment period. Urinalysis

collected during the follow-up period were used as a

measure of post-treatment performance, along with

self-report.

Mini International Neuropsychiatric Interview
International Mental Status
MINI International Mental status

(Sheehan et al.,

1998). A truncated version of the MINI was administered to
confirm diagnosis inclusion criteria. Only the modules on

Psychotic disorder, bipolar disorder I and II Major

Depressive disorder, and alcohol/drug dependence were
included in the interview. The interview was clinician
administered. Every module began with a single screening

question corresponding to additional symptoms. This

screening question format meant participants could be
asked between 4 and 72 questions depending on their level

of psychiatric severity and substance use history. Trained
and supervised research assistants administered the MINI
as a structured interview. The MINI demonstrates good

internal validity with all nine pathology dimensions with
a coefficients ranging from .71 to .85, and acceptable
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test-retest reliability, with correlation coefficients

ranging between .68 and .91. Concurrent validity between

the BSI and the SCL-90-R were high along all dimensions of
the MINI with r between .92 and .99

(Lecrubier et al.,

1997; Sheehan et al., 1998)
Positive and Negative Syndrome Scale

The Positive and Negative Syndrome Scale
et al.,

1987)

(PANSS)

(Kay

is a commonly used, 30 item clinician-rated

measure. It assesses severity of positive and negative
symptoms of schizophrenia or other psychotic disorders
based on researcher observations and ratings. Symptoms
were individually rated (1 = absent to 7 ~ Extreme). The
PANSS produces a total score and three sub-scale scores

for positive symptoms, negative symptoms, and general
psychopathological symptoms. Items in the PANSS
demonstrates good internal consistency with overall ot
coefficients for the positive and negative scales .73 and

.83 respectively. The scale for general psychopathology
generated a good internal reliability with an ot
coefficient of .79. Inter-rater reliability between PANSS

sub-scales were good, r - .83 to .87. The PANSS was
administered by trained and monitored researchers.
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Brief Symptom Inventory

The Brief Symptom Inventory (BSI)
1992)

(BSI; Derogatis,

is a 53 item self-report Likert type scale with

items rated from 0 - "not at all" to 4 = "Extremely" . The
BSI is an abridged scale developed from the larger Symptom
Checklist-90

(SCL-90-R; Derogatis,

1983)

and measures

current psychiatric distress. The BSI measures nine

separate symptom dimensions: somatization,
obsessive-compulsive,

interpersonal sensitivity,

depression, anxiety, hostility, phobic anxiety, paranoid

ideation and psychotic symptoms. Additionally the BSI can
be used to generate a global symptom score. The

scale-by-scale correlation of the BSI with the SCL-90 is

high r = .92 to .96 across all dimensions, and showed good
test-retest reliability with across all symptom dimensions
correlations between .68 and .91. Test-retest reliability

was also high across the three global scores r between .80

and .90. Internal consistency between symptom ranged from

acceptable to good with alphas between .71 and .85
(Derogatis & Melisaratos, 1983) .

Addiction Severity Index-Lite
The Addiction Severity Index-Lite (ASI-L; McLellan,
Cacciola,

& Zanis,

1997)

is a shortened version of the

standard Addiction Severity Interview (ASI; McLellan,
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Luborsky, Woody, & O'Brien,

1980), the gold standard

instrument for measuring addiction severity in addiction

research. The semi-structured ASIL interview can be
administered in 15 to 30 minutes and assesses information

on the participants' drug and alcohol use,

legal and

family history, social relationships, and psychiatric
symptoms. Each of these seven areas is assigned a rating

from 0 to 9 by the interviewer representing the severity
of problems in that specific domain. Concurrent validity,
as measured comparison to the full AST, was found ranging

from acceptable to good for all sub-scales
.89) except for the family-social sub-scale

(a = .54 to
(a = .20)

(Cacciola, Alterman, McLellan, Lin, & Lynch, 2006).

Inter-rater reliability was found to be the same as the
ASI,

(a = .85 to .90 across sub-scores and general scores)

(McLellan et al., 1980)
Self-Report Service Utilization
Self-Report Service Utilization (SRSU). In order to
characterize treatment utilized from the TAU supplied by

the community mental health clinic, a 6 item form was
created that inquired about treatment received in the

previous week. The questionnaire inquired about medical
services received in the previous week, mental health
services received in the previous week, and substance
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abuse services received in the previous week. This
questionnaire was administered as a survey.
Coding Non-Linear Variables
Non-linear variables, gender, and ethnicity were

coded as dichotomous variables. Gender is naturally

dichotomous, and was coded such that male gender was coded

as "1" and female gender was coded as "2". Ethnicity data
was collected as five separate categorical variables. For

our analysis ethnicity was dichotomously coded with ethnic
minority coded as "1", and non-ethnic minority coded as

"2" .
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CHAPTER FOUR

RESULTS

Statistical Analysis

Only participants in the active CM treatment
condition were included in study analyses. A four-step
Hierarchical linear regression was used to test both
in-treatment and post-treatment predictive models. The

dependent variable for the in-treatment model was the
longest number of consecutive appointments without

stimulant-positive urine samples or missed appointments

during treatment (maximum 36 possible) . For the
post-treatment time period, number of self-reported days
of stimulant use in the previous month will act as the

dependent variable. The independent variables will be

specific service utilization variables taken from the

SRSU, psychiatric variables taken from the BSI and PANSS
and drug use severity variables taken from the ASI-L. Step
one of the four step regression model was demographic
variables; age, gender,

and ethnicity to control for them.

The second step was substance use related variables. These

variables were stimulant-positive urinalysis at baseline,
and ASI drug use composite score. During analysis of
post-treatment predictors, in-treatment performance was
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added as an independent predictor at this step. The third

step of the regression was psychiatric severity variables,

namely the BSI global severity score, and PANSS composite
score, and schizophrenia-spectrum vs. mood disorder

diagnosis. The fourth and final step, was service

utilization variables; number of outpatient psychiatric

care contacts in the week prior to intake, and number of
outpatient substance abuse treatments attended in the week

prior to intake. All variables were checked for
inter-correlation to guard against issues with
multi-coliniarity.

Hypothesized Models
Three hierarchical regression analyses were performed

to assess both in-treatment performance (stimulant
urinalysis)

and post-treatment stimulant use outcomes

(stimulant urinalysis and self-report of stimulant use).

The dependent variable for the in-treatment performance
regression model was operationalized as the highest number

of consecutive stimulant-negative urinalyses submitted

during treatment. Missing samples caused by absences or
refused samples were counted as stimulant-positive and

thus interrupted the consecutive number of stimulant clean
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urines. This allows for the possibility of a maximum of 36
clean samples, and a minimum of zero.

The two separate dependent variables for the two
post-treatment performance regression models were

self-report of stimulant use in the previous month during
follow-up visits (assessed by ASI-Lite) and number of

stimulant-positive urinalyses collected during three
follow-up visits. Self-report of stimulant use, and

urinalysis results were averaged across follow-up visits
attended to account for missed follow-up appointments.
Predictors of In-Treatment Performance

Demographic variables

(age, gender, and ethnicity)

were entered in the first step of the hierarchical

regression analysis predicting the highest consecutive

clean urinalyses during treatment. As a group, these
variables did not account for a significant amount of
variance (F (3,

79)

= .030, p > .05).

Drug use related variables (i.e., ASI-L drug use
severity composite score and stimulant positive urinalysis

at baseline) were entered in the second step of the model.
These drug use variables accounted for an additional 13.5%
explanatory variance (F (2,

77)

= 6.02, p < .005) due

primarily to the effect of a stimulant positive urinalysis

at baseline.
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Psychiatric symptomology (i.e., PANSS symptom
severity composite score,

the BSI global composite score,

and schizophrenia-spectrum disorder vs. mood disorder)
were entered in step three of the model and accounted for

10.9% additional explanatory variance (F (3, 74)

= 3.55,

p < .05) due primarily to the effect of BSI global

symptoms. Specifically, BSI composite scores were
negatively correlated with consecutive clean urinalyses.

Service utilization at pre-treatment (i.e., number of

psychiatric outpatient appointments in the week prior to
treatment, and number of outpatient chemical dependency

services utilized in the week prior to intake) were
entered in step four and accounted for an additional 12.9%
explanatory variance (F (2, 72)

= 7.42, p < .05)

due

primarily to the effect of psychiatric service
utilization. Psychiatric services were positively
correlated with in-treatment consecutive clean urinalyses

See Table 3.
Predictors of Post-Treatment Performance

Two separate hierarchical regression analyses were

conducted to assess predictors of post-treatment
performance See Table 4 and Table 5. The first model

presented utilized the self-report of stimulant use data
collected during follow-up as the criterion. Demographic
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variables collected at intake (age, gender and ethnicity)
were entered in the first step of the model and accounted

for 18.3% explanatory variance (F (3, 47)

= 3.51, p < .03)

due primarily to the positive correlation between of

gender and self-report stimulant usage post treatment.
Drug use related variables (i.e., ASI-L drug use

severity composite score and stimulant positive urinalysis

at baseline) were entered in the second step of the model
and accounted for 6.7% additional variance, however this
result was not statistically significant

(F (3, 44)

= 1.31, p > .05) despite the fact that both

ASI-Lite drug use severity score (p = -.14), and
in-treatment consecutive clean urinalyses

(p = -.23) both

reached above what would be considered a small effect size
using Cohen's effect size estimations.

Psychiatric symptomology (i.e., PANSS symptom
severity composite score,

the BSI global composite score,

and schizophrenia-spectrum disorder vs. mood disorder)
were entered in step three of the model and accounted for

8.1% additional variance, however this result was not

statistically significant

(F (3, 41)

= 1.65, p > .05). Of

these variables, BSI global composite score (p = .32)
reach a medium effect size, and both PANSS
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did

(p = -.14), and

schizophrenia-spectrum disorder

(p = .16)

achieved above a

small effect size by Cohen's size estimates.
Service utilization at pre-treatment (i.e., number of

psychiatric outpatient appointments in the week prior to
treatment, and number of outpatient chemical dependency

services utilized in the week prior to intake)was entered

in step four and accounted for an additional 4.4%
variance, however this effect was also not statistically
significant

(F (2, 39)

= 1.36, p > .05) despite both

variables contributing what is considered above a small
effect (outpatient psychiatric services,
outpatient drug services,

p = -.17;

p = -.11) See Table 4.

The second post-treatment outcome model utilized

urinalyses collected during the three monthly follow-up
appointments as the dependent variable. To account for

missing follow-up data, the total number of stimulant
positive urinalyses was recorded, between 1 and 3. This
score was then averaged across the number of visits the
clients attended to generate a proportion of dirty

urinalyses submitted during follow-up visits attended.
Demographic variables were again entered into the first

step of the regression accounting for 9.9% of the
explanatory variance with the minority status variable

reaching a medium effect size
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(p = .31), however this step

represented a statistically non-significant increase in

variance (F (3, 49)

= 1.79, p > .05). The second step,

drug use variables,

(i.e. stimulant-positive urinalysis at

baseline, ASI-Lite drug use severity composite score, and
consecutive clean urinalysis) accounted for an additional

17.1% of variance in the total model. This increase was
significant over the previous step (F (6,

46)

= 3.58,

p < .05). This effect was due primarily to the strength of

the positive correlation between the dependent variable,
stimulant-positive baseline urinalysis

(p = .267),

consecutive clean urinalyses in-treatment

(p - .25), and

the negative correlation between the dependent variable
and the ethnicity variable. Psychiatric variables

consisting of the PANSS composite score, schizo-spectrum

vs. mood disorder, and BSI composite score, were entered
next and accounted for an additional 5.9% of variance

which was not a statistically significant difference over

the previous step (F (3, 43)

= 1.46, p > .05). The impact

of the schizophrenia-spectrum disorder variable did nearly
reach what would be considered a medium effect size

(p = -.27). Service utilization at pre-treatment

(i.e.,

number of psychiatric outpatient appointments in the week
prior to treatment, and number of outpatient chemical
dependency services utilized in the week prior to intake)
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was entered in step four and accounted for an additional
8.6% explanatory variance, however this effect was not

statistically significant

(F (2, 41)

but outpatient substance treatment

= 3.006, p > .05),

(p = -.37) would be

regarded as having a medium effect size according to
Cohen's estimates See Table 5.
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CHAPTER FIVE

DISCUSSION

With limited, availability of resources for treatment

of COD, it is important to use findings about predictors
of treatment performance to inform treatment decision

making. The current study examines predictors of treatment

performance, treatment completion, and post-treatment
substance use in a SMI population, a population that is

too often excluded in treatment outcome research entirely.
Of variables examined to predict in-treatment

performance, stimulant-positive urinalysis at baseline,
BSI global score, number of outpatient psychiatric service

in the week prior to baseline were significant predictors
of in-treatment performance. Baseline stimulant-positive
urinalysis, and Higher BSI global composite scores were

associated with worse in-treatment performance

(e.g. fewer

consecutive stimulant-negative urinalyses). Number of

outpatient psychiatric services utilized in the week prior
to baseline, such as case manager contacts and mental

health group attendance, were- positively associated to
better in-treatment performance.

Post-treatment performance, as measured by
self-report stimulant use averaged across follow-up visits
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attended was significantly predicted by gender, ASI-lite
drug use composite score, and BSI global severity index.

Female gender and higher BSI global psychiatric severity
score were positively associated with greater self-report
post-treatment stimulant use. Interestingly, higher

ASI-Lite drug use composite score was related to lower
stimulant use at post-treatment.

The other measure of post-treatment outcome,
stimulant-positive urinalyses averaged across follow-up
appointments attended, was significantly predicted by

minority status, Schizophrenia spectrum disorder, and
outpatient drug treatment service utilization. Minority
status positively correlated with a higher proportion of
stimulant positive urinalysis submitted during follow-up.

Having a schizophrenia-spectrum disorder and greater

utilization of outpatient substance abuse services was
associated with lower number of stimulant-positive

urinalyses at follow-up.
Interestingly, no variable consistently predicted
performance across all treatment outcome measures;
in-treatment performance, treatment completion, or

post-treatment drug use. A higher BSI global score was

positively associated with poorer in-treatment
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performance, but only trended toward significant
prediction of self-report post-treatment outcome.

While some of the results of the current study mirror

work done in the non-SMI population, important clinical
insights can be gained about predictors of treatment

outcomes in SMI population from the current research. The
impact of urinalysis results at intake have been a
reliable predictor of treatment outcome (Peirce et al.,

2009). This finding is replicated in our population of

adults attending CM treatment, however this pattern did
not hold true as a predictor of post-treatment stimulant

use. More importantly,

initial UA may be acting as an

independent measure of addiction severity. The inability

of a client to submit a clean urinalysis at intake may
suggest ambivalence about treatment initiation. At the

very least,

the social science axiom stating previous

behavior is the best predictor of future behavior again,
is supported this finding. Female gender and minority
ethnic status were both associated with poorer
post-treatment outcomes

urinalysis respectively)

(self-report and post-treatment
similar findings have been seen

in non-SMI populations (Hillhouse et al., 2007). Since
these variables differentially predict the post-treatment

results, care must be taken in interpretation of the
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finding. Female gender predicted more self-report

stimulant use, but not post-treatment stimulant positive
urinalysis. This may be due to a greater willingness to

divulge stimulant use during the follow-up period from

females. Interpretation of the ethnicity finding may prove
more challenging. Minority status predicted higher
proportion of stimulant positive urinalyses collected

during post-treatment but not higher self-report stimulant
usage. This may be due to poorer rapport between the
researcher and client, or may be a geographical difference

between minority and non-minority SMI populations. With
both populations having a large number of under-housed and
homeless individuals,

there may be a fundamental

difference in the geographic area they choose to

congregate such that there is a higher availability of
stimulants in the geographic locations where homeless

minorities choose to frequent. However, this theory is

based only on clinical experience; scant research is done

on the movement patterns of homeless individuals,

let

alone, minority homeless with SMI.
Other predictors of in-treatment performance found
apply distinctly to the SMI population examined here.

Higher BSI global score, a self-report measure of

discomfort caused by psychiatric symptoms such as anxiety
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and depression, was associated with poorer in-treatment

performance. Neither the PANSS, an interviewer rated

measure of psychiatric symptom severity, or a current

diagnosis of a schizophrenia-spectrum disorder predicted
in-treatment outcome. This pattern of results was repeated

in the post-treatment self-report stimulant use outcome

further underscoring the importance of psychiatric
distress on treatment outcome. Both Compton,

Cottier,

Jacobs, and Ben-abdallah (2003) and Hillhouse et al.
(2007) observed the negative impact of psychiatric

distress caused by depression and anxiety on substance use
outcomes in-treatment and post-treatment. This suggests

that psychiatric distress is driving poorer performance,
but the presence of a schizophrenia-spectrum disorder or
even the severity of psychotic symptoms does not. In fact,

the post-treatment drug use outcome suggests that having a
schizophrenia-spectrum disorder was associated with a

lower proportion of stimulant-positive urinalyses at

follow-up. Thusly, a client who feels that their
psychiatric problems are well managed could perform well

in COD treatment regardless of how psychiatrically severe
they present to clinicians and interviewers. This is

contrary to the findings of Brown, Li, Bennett, and
Bellack (2011) who showed the presence of a
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schizophrenia-spectrum disorder was associated with poorer
treatment engagement. However,

the poorer treatment

engagement may be an artifact of the procedural issues
during their study. The intake for the Brown, Li, Bennett,

and Bellack consisted of two,

2.5 hour long interviews

across two days. Their true finding may be that people

with schizophrenia-spectrum disorders have difficulty

completing lengthy intake procedures, as opposed to having
difficulty engaging in treatment.

Similar to the findings of Mclellan et al.

(1994),

active service utilization in the form of outpatient

psychiatric and substance abuse treatment utilization was
associated with positive in-treatment and post-treatment

performance. Interpreting this in tandem with our finding

on the impact of psychiatric distress, we may be seeing

that participation in psychiatric services are lowering
psychiatric distress, and leading to better in-treatment

performance. This further underscores the need for
wrap-around treatment services that address both substance

abuse issues and psychiatric disorders simultaneously.
Conversely the treatment utilization variable can be

interpreted in another way; the number of clinical care

contacts a client is receiving is directly beneficial to
their drug treatment or this variable can represent the
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client's integration into the TAU milieu of the outpatient
psychiatric clinic where they receive services.
Unfortunately there is no way to differentiate between

these two interpretations with our data, but it is clear

that service utilization acts as a supportive factor
during substance abuse treatment.

Clinical Implications
Applications for these findings are relatively

straight forward. CM was regarded by our participants as a

highly desirable substance use program to participate in.
Requiring a client to submit a single clean initial UA

prior to treatment enrollment may be an appropriate, and

not too challenging first hurdle for clients to meet. This

may distinguish clients who are ready to succeed from
those who may be experiencing ambivalence towards

treatment. That being said, the unique mechanism of CM
treatment allocates resources directly to clients who do

well in treatment. This is fundamentally different from
more conventional forms of treatment such as IOP and
inpatient treatment where treatment failure often leads to

costly dropout and re-admissions.
Outpatient psychiatric service utilization acted as a

predictor of better in-treatment performance. This may
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suggest that it is beneficial to approach clients who are

actively participating in their mental health treatment
despite struggling with substance abuse problems.

Additionally, participation in outpatient substance abuse

services predicted fewer stimulant positive urinalyses
during treatment follow-up. This may suggest CM can also
function well as an adjunct treatment while a client is

receiving other types of Substance abuse services.

Unlike previous research, our findings showed
schizophrenia-spectrum diagnosis had no negative impact on

treat outcomes in-treatment or and may have a positive

effect on post-treatment outcomes. Clinicians should
readily engage clients with schizophrenia-spectrum
disorders who are seeking substance use treatment.

Limitations
Clear limitations exist in the present study. The

attrition rate between the baseline and follow-up time

points was large (N = 96 at baseline,

to N = 52 at

follow-up). While this is common in substance abuse
treatment outcome studies,

it limits the power of the

results of post-treatment analysis. Additionally,

previous studies

while

(Compton et al., 2003) have found similar

predictors of treatment outcome across types of drugs
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used, the current study's focus on stimulant drugs may

limit generalizability of these findings to other
populations of substance user. Also,

the reliability of

self-report data in substance abuse studies are often

considered a weakness (Del Boca & Noll, 2002). The fact

that we were able to bolster the self-report data with
urinalyses at the post-treatment time-points is helpful.
Lastly, the study's unique strengths,

it's focus on CM a

wholly behavioral treatment intervention for substance
abuse, may also be a weakness limiting the
generalizability of these findings to other types of more
conventional substance abuse treatments.

Future Research

The persistence and strength of BSI finding on the
in-treatment outcome poses interesting questions for

future research. Further examination of what particular

symptoms and what levels of severity are driving these
results could help clinicians develop a short

questionnaire to assess psychiatric distress that limits
performance in-treatment. Again this could be used as a

screening for enrollment to treatment, or inform
clinicians about how best to target mental health

treatment prior to substance abuse treatment.
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Tabled.
Descriptive analysis of non-dichotomous variables
N

Mean(SD)

Min/Max

Alpha
coefficient

In-tx consecutive UA

96

8.44(11.7)

0/35

*

Self-Report Post-Tx Avg.

62

2.0(4.4)

0/29

*

Follow-up Stim-Positive UA

61

.33(.4O)

0/1

*

Age at Baseline

96

43.5(9.3)

22/62

*

AS1 Drug Severity

96

.16(.1O)

.00/.41

.49

BS1 Psych Severity

96

1.63(.75)

.21/3.45

.95

PANSS composite

96

-.12(.86)

-2.86/2.71

.77

Outpatient Psych services

83

1.98(2.12)

0/9

*

Outpatient Drug Tx.

83

1.13(1.78)

0/7

*
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Table 2.
Bivariate Correlation Analysis for Study Predictor Variables
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

1. Gender
2. Age

-.17

3. Minority Status

.11

-.02

4. UA at Baseline

-.09

.18

-.13

5. AS I drug composite
score

.09

-.18

.17

6. In-tx Consecutive UA

-.03

.08

-.05 -.34
*

7. PANSS Composite

-.07

.04

.03

*
.31

.18 -.26
*

8. BSI Global Severity

-.01

-.06

.06

.03

*
.35

*
-.27

*
.32

9. SchizophreniaSpectrum Dx.

.10- -.11

-.09 -.20

.04

*
.23

*
.28

-.27

10. Outpatient Psych.
Service

.09

11,. Outpatient Drug Tx.

.14 -.24
*

*
.23

-.19

-.08 -.06

.06

.12

*
.28

.02

.16

.03

-.08

.03

.09

.10

-.12 -.01

.10

Note:*p < .05
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*
.54

Table 3.
Hierarchical Regression Predicting In-Treatment Performance, Consecutive
Stimulant-Clean Urinalyses From Demographic, Drug Use, Psychiatric
Severity, and Service Utilization Variables
AR2

R2

P

P

.001

.001

-.01

.96

Age

.03

.90

Minority Status

.01

.80

-.04

.72

Age

.07

.82

Minority Status

-.03

.54

Stimulant-Positive UA at Baseline

*
-.35

*
.003

ASI-Lite Drug Use Severity

-.07

.54

-.07

.53

Age

.09

.88

Minority Status

-.02

.38

Stimulant-Positive UA at Baseline

*
-.34

*
.005

ASI-Lite Drug Use Severity

.04

.73

PANSS psych severity

-.07

.54

BSI global severity

*
-.28

*
.02

.10

.40

-.01

.89

Age

.10

.96

Minority Status

-.01

.31

Stimulant-Positive UA at Baseline

*
-.36

*
.002

ASI-Lite Drug Use Severity

.03

.78

PANSS psych severity

-.07

.53

BSI global severity

*
-.35

*
.003

Schizophrenia-spectrum disorder

.07

.52

Outpatient psych services

*
.42

*
.001

-.11

.36

Step Model Variable
1.

2.

3.

Gender

*
.135

Gender

*
.109

Gender

*
.136

*
.245

Schizophrenia-spectrum disorder

4.

*
.129

Gender

Outpatient drug services
Note:* p< .05; + p< .10
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*
.374

Table 4.
Hierarchical Regression Predicting Post-Treatment Self-Report Stimulant Use
From Drug Use, Psychiatric Severity, and Service Utilization Variables
Step Model Variable

AR2

F?

Std. p

P

1.

*
.183

*
.183

*
.41

*
.004

.08

.56

-.22

.11

*.41
.04
-.18
.05
-.14
-.23

*.005
.78

*.43
.03
-.06

*
.003

Stimulant-Positive UA at Baseline
ASI-Lite Drug Use Severity

.12
-.315+

.46

In-treatment consecutive clean UA
PANSS psych severity
BSI global severity

-.13

Gender

Age
Minority Status
2.

Gender

.067

*
.250

Age
Minority Status
Stimulant-Positive UA at Baseline
ASI-Lite Drug Use Severity
In-treatment consecutive clean UA

3.

Gender
Age

.081

*
.330

Minority Status

.73
.31
.13

.84

.70
.05+

-.14
-.32+

.34
.06+

.16

.31

*
.45

*
.002

Age
Minority Status
Stimulant-Positive UA at Baseline

-.01
-.06

.67
.94

.20

.27

ASI-Lite Drug Use Severity
In-treatment consecutive clean UA

*
-.32

Schizophrenia-spectrum disorder
4.

.20

Gender

.044

*
.374

PANSS psych severity

.15

*.04
.83
.34

BSI global severity
Schizophrenia-spectrum disorder

*.41
.14
.-17
-.11

*.02
.39
.45
.55

.04

Outpatient psych services
Outpatient drug services
Note:* p < .05; + p<.10
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Table 5.
Hierarchical Regression Predicting Post-Treatment Performance,
Stimulant-positive Urinalyses From, Drug Use, Psychiatric Severity, and
Service Utilization Variables
Stef? Model Variable

AR2

R2

Std. (3

P

Gender
Age
Minority Status

.099

.099

-.02
.07
*
-.31

.89
.61
*
.032

Gender

*
.17

.04

.75

.01

.94
.05+

1.

2.

*
.269

Age

-.269+
.268+
-.07
-.25+

Minority Status
Stimulant-Positive UA at Baseline
ASI-Lite Drug Use Severity
In-treatment consecutive clean UA

3.

.059

Gender

*
.328

Age
Minority Status
Stimulant-Positive UA at Baseline

.59
.08+

.05

.68

.001

.99
*
.02

*
-.338

.14
-.04

.40

-.25
.06
-.20

.12

-.27+

.08+

.12

.36

.03
*
-.34
.16

.83
*
.02
.35
.75

In-treatment consecutive clean UA

.05
.14

PANSS psych severity

.06

BSI global severity

.18

.65
.33

*
-.34

*
.03

.10

.61

*
-.37

*
.02

ASI-Lite Drug Use Severity

In-treatment consecutive clean UA
PANSS psych severity
BSI global severity
Schizophrenia-spectrum disorder
4.

.08+

.086+

Gender

Age
Minority Status
Stimulant-Positive UA at Baseline
ASI-Lite Drug Use Severity

Schizophrenia-spectrum disorder

Outpatient psych services
Outpatient drug services
Note:* p < .05; + p <. 10
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*
.414

.82
.70
.24

.46

Table 6.
Standardized Beta Weights Across Three Outcome Prediction Models
Predictor
Variables

In-Treatment
Performance

Post-Treatment
Self-Report

Post-Treatment
Urinalysis

-.01

*
.45

.12

.10

-.01

.03

Minority status

-.01

-.06

*
-.34

Stimulant positive at
baseline

*
-.36

.20

.16

.03

*
-.32

.05

-

.04

.14

PANSS Comp

-.07

.15

.06

BSI global COMP

*
-35

*
.41

.18

Schizo-spectrum
vs. Mood disorder

.07

.14

*
-.34

Psych. Services

*
.42

.-17

.10

-.11

-.11

*
-.37

Demographic gender
Variables
Age
Drug Use
Variables

ASI Drug Comp
In-treatment
performance

Psychiatric
Variables

Service use
Variables

Substance use
services
Note:* p< .05; + p <. 10
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UNIVERSITY OF WASHINGTON
CONSUMER CONSENTFOHAI
CONTINGENCY MANAGEMENT OF STIMULANT USE

received
Human Sub/octsDivision

MAY 2 7 2010

uw

Principal Investigator:, RichardRics,M.D. Professor,
Department ofPsychiatry andBehavioral Sciences, University of Washington, 206-897'4226
Co-Irivesti gator: Debra Srebnik. Ph.D.. Associate Professor
Department of Psychiatry and Behavioral Sciences, University of Washington, 206-263-8940
Protect Manager: Michael McDcncIl/Ph.D., Acting Assistant Professor
Department of Psychiatry and Behavioral Sciences, University of Washington, 206-744-9971.
Research Coordinator Frank Angelo,. Research Coordinator,
Department of Psychiatry and Behavioral Sciences; University of Washington, 206.744-1769.
Research Coordinator: Christina Raincv. Research Coordinator •
Department of Psychiatry and-Behavioral Sciences, University of Washing lbri,;206 744-1769
Research Assistant: Andrea Sugar, Research-Assistant,
Department of Psychiatry and Behavioral Sciences, University ’of Washington,.2Q6 <744-4769

.

Investigators1 Statement:

We arc asking yon to be in. a research study. The purpose of this.conscnt fonn is:to.give you the
information you need to help you.decide whether or not to be in the study. Please.read the fonn
carefully. You can ask questions about the purpose of the research, what we would ask you to
do, the possible risks and. benefits, your rightsas a volunteer, and 'anything else about the
research or fens form that is not clear. When all'of your questions have been, answered,you can
decide if you want to be in the study, or not. This process is called "informed consent’1,

PURPOSE OF THE STUDY
This is a study abouf'contingency management trealuicnt. Contingency management treatment’
means that a'perscn is:rewarded for not using drags :by drawing for a chance to win prizes.

The firstpurpose of this study is to find out whether 12 weeks of contingency management
treatment helps people change their use ofdrags. The second purpose of the study is to find out
whether contingency management changes mental illness symptoms, healtE-riskbehaviors,
smoking, employment, involvement in treatment, and community, problems like homelcssncs§,pp^.
jail bodkings, hospitalizations, emergencyToom visits.
” ,
JUN U 3 ?010 ,

STUDYPROCEDURES
■- ■
1 ■

Uw Wi»

fieWfComiBitUjet

Admission procedures
If you decide to participate we.will first contact your case manager or other clinicianat
Community Psychiatric.Clinic (CPC) to make sure that you receive services at CPCftmd thatitis
safe for you to be ‘bf the- study. After we make sure the study is a good, fit for you, you will, be:
asked to complete an admission interview. This interview asks, about your drug and alcoholuse
(including injection drag use) ml cravings, medical history, health risk behaviors and sexual
partners, smoking, current treatment,.mental.health and substance use' services, and mental
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,

illness symptoms. You will bo asked to give urine and breath samples that will bc tested for drug
and alcohol use. We will also askyou to give us the names and contact in formation of people we
can contact in an emergency or if we liavc difficulty reaching you. These admission procedures
will take about2 hours and you will get a $30 voucher to a local grocery store for dding'thcm.

Reward Groups
After you complete the admission interview you will be randomly placed (by chance like
flipping a coin) to one of two groups. The researchers liavc no control over what-group you will
be in. You will have an equal chance of being placed to one of the twostudy groups.
No matter what group you are in you will be asked to give urine and breath samples three times a
weckfpr 12 weeks, Aller you. give a urine sample, you will get to make "draws" for prizes of
different sizes. There is a 50-50 chance of getting some prize with each draw. Some prizes arc
small (like gum, bus passes, toothbrushes), some are large (like watches, portable CD players,
gift cards), and a few arc jumbo (like a DVD player or micro wave). You will not get to draw
for prizes if you have a breaih-alcohol level of more, than .05.
The two groups are:

Contingent Rewards group - If you are in this group you will earn the chance to. make
^draws’1 for prizes when your weekly urine samples show no signs of using .stimulants,
like cocaine, methamphetamines, or,amphetamincs. You will get a bonus draw if your
samples also show no signs of using other drugs or alcohol.
You will earn one extra draw for every 3 times in a row that your samples show no signs
of using stimulants. If you have not used stimulants during the 2nd week you will get 2
draws (plus a possible. I more for not using other drugs or alcohol), the 3rd week you will
get three draws (plus 1 possible bonus draw). If you doiffuse stimulants the number of
draw’s you get will keep increasing. If you use stimulants again, you will go back to only
one draw, but ifyou then have 4 samples in a row of not using, you will go back to. foe
number of draws you had earned before you used.

Random Rewards group - If you are in.lhis group you will get to make ‘‘draws’- for
prizes, but the number,you get will not be based.on whether your tests are positive for
'drugs.' The researchers will, set the number of draws you get ,for providing urine and
breath samples three times a week. You will cam prizes even if your urine tests are
positive for drugs,,

No matter what group you are in you will keep.gcttmg regular treatment from Community
Psychiatric Clinic;

APPROVED
JUN 03?D1G

UtV HiKTjan Scb&ato
Rating scales during reward period
Revfew CcWHiftee
Once each week In the 12 weeks of drawings we will ask you to tell us how much you are
craving drugs and alcohol and what mental health and substance use, services you liavc used in
the last week. We will-ask you about any changes in your physical or mental health, like
whether you've been feeling like you might hurt yourself or someone else, and whether you had
to go to a hospital or emergency room. Giving urine and breath samples, drawing prizes and
'answering these questions will take about 10 minutes 3 rimes each week for 12 weeks.
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Once each-month in the 12v,’ceksof drawings, we will'ask you questions about drug and alcohol
use, health risk behaviors and sexual partners, and mental illness symptoms. This will take about
30, minmes;

Follow-up period
After lire 12 weeks of drawings, we will ask you to give urine and breath samples once a month
for 3 more months. You will be asked the same questions about drug and alcohol use'and
cravings, health risk.liehaviors,and sexual partners, mental health and substance use services, and
mental illness symptoms. This will take 30 minutes. You won’t get to draw fbr.prizes but you
will get a S 20. grocery store gift, paid for the first 2 months and a $30 gift:Card for the last month:
Case manager ratinas
For foe study, we will ask your case manager to rale yout tnental illiiesssymptomsf substance: .
use, treatment attendance and overall functioning. Case.managers will do these ratings when you
begin foe study,- oncca month during the l^-week reward period, arid at foe'end ofthe' 3-month
follow-up period.
*

Record review
If you agree to be in this Study, we;will collect electronic records about any incarcerations,
outpatient substance.abuse treatment, deiox/sobering centcr’admissions, mental health diagnoses
and outpatient services. We will also collected information about changes in you living situation,
you have had in King County and nny. hospitalizations or emergency room visits statewide. We
.will get this information about 9 months of your life (S monfos before and 6 after you agree to be
in the study).

RISKS, STRESS, and DISCOMFORT
Il is poss i ble1 that yqu will continue to use drugs and that t he: study wilt not help you stop. There
is also a very small risk that the. confidential information you provide to foe study wiU be seen by
someone who is not allowed to see it. We describe how wc will.try' lb prevent this In the OTHER
INFORMATION section of this form.

Yo.u may experience discomfort Dr embarrassment because of foe results of your urine or. breath
samples or because some of foe questions wc will ask are about substance use, mental illness
symptoms and health risk behaviors.
If you- feel you have been injured becauseof the study.please,'contact Dr, Ries,

ALTERNATIVES TO TAKING PART IN THIS .STUDY
If you do notwant to participate in the study,it will not change your, treatment at Community
Psychiatric Clinic. You do.not have to be in fols study to receive treatment You may alsobe AFPROVED
helped by free 12-Slep groups (e.g., Narcotics Anonymous).

dON 037010

BENEFITS OF THE STUDY

:

•nwhrA
Your participation in one of foe research groups may help you to reduce or stop your stimulant,
use, but we cannot guarantee this. The results of this study may help, researchers.figure cut
treatments that work
*
for foe ’treiitmeritof stimulant abuse.
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OTHER INFORMATION

Your participation in this research is VOLUNTARY. You mhychoosu not to participate, stop
your participation at any time,.or not answer any question .we.'may aslcyqu and it will not change .
your treatment with Community Psychiatric Clinic or ymir right to health care or other services *
at other agencies..
Your participation may be stopped by the study team if they feefthat your' participation would
put you or others in danger.

All information lhc study obtains abaut you will ’.CONPIDENTlAL. None qf your answers will
be shared with your case, manager, other providers or family or friends: Your answers will be
only be marked <with a code number, not with your name/ We will keep a'link between this code
and your name. This link will be.kept by (he principal investigator under lock-and-key.1 As much
as .is possible, we .will not “release any information about you to outsiders withoui ycur consent
We may release information about you in the event of an emergency or if wc learn that'you
intend to harm yourself or others.. If this happens, limited infpmuition will be-given to the staff
caring for you so they can help you.
Names and other personal identifiers will be destroyed one year after the study is over. This will
be in 2012. When the results of the research are published or discussed in conferences,, no.
information will be included that-would make it possible for others to figure out "that you
participated in the research.

If wc cannot.reach you during the study, vyc will try to find you through the people that you list
on the "Conlact SIiect." Wewill tell than that you are participating in a study at the University
of Washington and that you gave us their name to hdpfind you. Wc will not tell them anything
else about you Or the study.
Government or university istaff sometimes review studies such as this one to, make sure; they arc
being done safely and legally. If a' review of tins study takes place, your records may be'looked
at The reviewers will protect your privacy. The study records will not be .used to put you at
legal risk of harm.
Certificate of Confidentiality:

To help us protect your privacy, we have .obtained a Certificate of Confidentiality from the
Federal Government
With, this-1 Certificate, wc caimot be forccd'to release information in our research records:that
identify you, even by a court subpoeria^in any federal, state/ or lo cal civil, cri tninal,
administrative,-legislative,eor other proceedings.

JVN.03 ^010“

However, there,arc some;limits1 to the Certificate. It cannot be used to resist a demand for ( '
information from Authorized fcderafemplbyces, when they want the information to (1) audit or7
evaluate, a federally-funded'research project, or (2).meet the requirements of the federal Food
and Drug Administration.
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The Certificate does not prevent us from voluntarily disclosing identifiable information, We will:
make the following. voluntary, disclosures of identifiable information, wliich may include your
name. Anyof this information that is disclosed will not.be protected by tlrc Cci tificaic.of
Confidentiality.
• To the National Institute of Drug Abuse
• To state or federal pubEc health authorities to whom certain contagious diseases
*
(tuberculosis
*
HIV
anthrax, syphilis) arc reported (ifwe observe such diseases in any
subjects)
• To law enforcement authorities if we become a ware of information that suggests the
occurrence of child abuse
*
cider abuse, oryour intent to immediately and Substantially
harm yourself or others
• To-the-XJ-W Office that manages, payment to subjects: youriname, Social Security number,
*
address
and the name o f this study.
• To slate; federal; and institutional offices involved- in auditing; or compliance of rcscarc h,
risk management, patient safety, financial.controls...
The Certificate .of Confidentiality does not prevent you or a memberof your; family from
voluntarily releasing information' about yourself or” your involvement in this research If,you give,
your written consent to an insurer, employer, or other persemto receive rescarch mformation
about you, then wecan not use the Certificate to, withhold that information. .
The Certificate ofConfidentiality is nut an endorsement from theTcdprab Government fbr.our
research.

Printed name of study staff obtaining consent

Signature of staff obtaining consent Date

Subject's Statement;

This study has been explained to me. I volunteer to take part, in this research. I have had a
chance to ask questions. IfI have questions later about the research
*,!
can ask one df the
researchers listed above or callDr.rMcDoncll at 206 744-9971. In the case of a research related,
injury I can contact Dr .Ries at 206 897-4226. If 1 have questions about my rights as a research
*
subject
I can- call the Human Subj ccts Division at (206) 543-0098. I. give permission to the
researchers to use my medical and.jail records as described, in this consent form. I will receive, a.
copy of this consent form..
’

Printed name of subject
Copies to;

Signature of subject

Subject.
Investigator’s file

Date

APPROVED
JUN 03 2010

Ftevfw Odsrnrrurteo

69

CONTACTSHEET

In order to help us locate you for the second interview-and follow-up mailings, please provideyour address and telephone number and the names,.addresses andphone numbers for people who
may know where you would be at that time. These people can include friends and family
members.
Study ID__________

YOUR ADDRESS

YOUR TELEPHONE NUMBER
FRIENDS AND FAMILY

Relationship io you

Name”

Address

Phone number

Relationship .to you.

Name

Address

Phone number

Relationship to you

Name

APPROVED

Address.

JUN 03 ?mo
i.

Phone number
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Human Subjects Review Board
Department of Psychology
California State University,
San Bernardino

PI:

Lewin, Michael, & Angelo, Frank,

From:

Donna Garcia
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